How This Evidence Evolved
Overactive Bladder Treatment Ladder
From Anticholinergics to Neuromodulation and Combination Therapy
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Incontinence episodes per 24 h at final visit after 12 weeks: mirabegron 50 mg change −1.57 (95% CI −1.79 to −1.35) vs placebo −1.17 (−1.39 to −0.95); P<0.05
Daily incontinence episodes at 12 weeks: solifenacin 5 mg plus mirabegron 50 mg vs mirabegron 50 mg, adjusted difference −0.23 (P=.052).
Change in micturitions per day at 12 weeks: vibegron −1.8 vs placebo −1.3 (P<0.001)
Follow-up studies, subgroup analyses, and real-world validation
Daily urgency-incontinence reduction over 6 months: anticholinergic therapy 3.4 vs onabotulinumtoxinA 100 U 3.3 episodes (P=0.81)
Sustained moderate or marked improvement at 3 years: estimated 77% (95% CI 64–90) of selected initial responders
Daily urgency-incontinence reduction over 6 months: onabotulinumtoxinA 200 U 3.9 vs sacral neuromodulation 3.3 episodes (mean difference 0.63, 95% CI 0.13–1.14; P=0.01)
Daily UI change at week 12: onabotulinumtoxinA 100 U −2.95 vs placebo −1.03 episodes (P<0.001)
At least 50% urgency-incontinence reduction at 48 weeks: 68% (95% CI 60–76) in the intention-to-treat population
Current standard of care and ongoing research directions
Landmark Trials in This Story
Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder
Urgency episodes and incontinence episodes per 24 hours
Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study
Incident dementia with cumulative anticholinergic exposure
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Incontinence episodes per 24 h at final visit after 12 weeks: mirabegron 50 mg change −1.57 (95% CI −1.79 to −1.35) vs placebo −1.17 (−1.39 to −0.95); P<0.05
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Daily incontinence episodes at 12 weeks: solifenacin 5 mg plus mirabegron 50 mg vs mirabegron 50 mg, adjusted difference −0.23 (P=.052).
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Change in micturitions per day at 12 weeks: vibegron −1.8 vs placebo −1.3 (P<0.001)
Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
Daily urgency-incontinence reduction over 6 months: anticholinergic therapy 3.4 vs onabotulinumtoxinA 100 U 3.3 episodes (P=0.81)
Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
Sustained moderate or marked improvement at 3 years: estimated 77% (95% CI 64–90) of selected initial responders
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Daily urgency-incontinence reduction over 6 months: onabotulinumtoxinA 200 U 3.9 vs sacral neuromodulation 3.3 episodes (mean difference 0.63, 95% CI 0.13–1.14; P=0.01)
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Daily UI change at week 12: onabotulinumtoxinA 100 U −2.95 vs placebo −1.03 episodes (P<0.001)
Pivotal Study of Leadless Tibial Nerve Stimulation with eCoin® for Urgency Urinary Incontinence: An Open-Label, Single Arm Trial.
At least 50% urgency-incontinence reduction at 48 weeks: 68% (95% CI 60–76) in the intention-to-treat population
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.